» 
Latest progress from PharmNovo at EFIC
Copy URL
https://www.pharmnovo.com/post/pharmnovo-presents-new-results-at-efic-in-budapest

Latest progress from PharmNovo at EFIC

September 10, 2023

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

“We are very much looking forward to the congress and to describe our latest progress. PharmNovo is at the forefront of the field, pioneering the development of a delta opioid agonist. At this stage, we are more than ready to present our successful outcomes to the meeting, and to share these with our peers, investors, and collaborators”, says PharmNovo's Founder and Scientific Advisor, Bengt von Mentzer.

Bengt von Mentzer will be presenting two posters on PharmNovo's PN6047, our innovative drug candidate for neuropathic pain:

  1. Toxicity and safety testing of PN6047 – a delta agonist 
    In preclinical studies, PN6047 is shown to be safe and well tolerated with a wide estimated therapeutic window and lacking abuse potential. Preliminary results from the human phase I study show a similar profile and strongly indicate that PN6047 will be safe and tolerable and able to enter phase II efficacy studies in neuropathic pain patients.
  1. Antitussive activity of delta opioid receptor agonists 
    New data indicate that delta opioid agonists could provide a potential novel therapy for chronic cough without the unwanted effects, such as reduced respiration, of conventional non-selective opioids.

“Our successful phase I study was executed with professionalism and speed. We have now passed several important milestones and are well on our way in our mission to launch PN6047 as a compound for treating neuropathic pain and other conditions involving hypersensitivity in the nervous system. We are excited to enter the next, phase 2, stage of clinical testing with the potential of providing a new therapy to the millions of people suffering from neuropathic pain” says Bengt von Mentzer.

The European Pain Federation EFIC is a non-profit organisation representing healthcare professionals in pain management and science. 

To learn more about the Congress of the European Pain Federation and to explore the agenda for the world congress, visit: https://europeanpainfederation.eu/efic2023/

Author:
Copy URL
https://www.pharmnovo.com/post/pharmnovo-presents-new-results-at-efic-in-budapest

Latest progress from PharmNovo at EFIC

September 10, 2023

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

“We are very much looking forward to the congress and to describe our latest progress. PharmNovo is at the forefront of the field, pioneering the development of a delta opioid agonist. At this stage, we are more than ready to present our successful outcomes to the meeting, and to share these with our peers, investors, and collaborators”, says PharmNovo's Founder and Scientific Advisor, Bengt von Mentzer.

Bengt von Mentzer will be presenting two posters on PharmNovo's PN6047, our innovative drug candidate for neuropathic pain:

  1. Toxicity and safety testing of PN6047 – a delta agonist 
    In preclinical studies, PN6047 is shown to be safe and well tolerated with a wide estimated therapeutic window and lacking abuse potential. Preliminary results from the human phase I study show a similar profile and strongly indicate that PN6047 will be safe and tolerable and able to enter phase II efficacy studies in neuropathic pain patients.
  1. Antitussive activity of delta opioid receptor agonists 
    New data indicate that delta opioid agonists could provide a potential novel therapy for chronic cough without the unwanted effects, such as reduced respiration, of conventional non-selective opioids.

“Our successful phase I study was executed with professionalism and speed. We have now passed several important milestones and are well on our way in our mission to launch PN6047 as a compound for treating neuropathic pain and other conditions involving hypersensitivity in the nervous system. We are excited to enter the next, phase 2, stage of clinical testing with the potential of providing a new therapy to the millions of people suffering from neuropathic pain” says Bengt von Mentzer.

The European Pain Federation EFIC is a non-profit organisation representing healthcare professionals in pain management and science. 

To learn more about the Congress of the European Pain Federation and to explore the agenda for the world congress, visit: https://europeanpainfederation.eu/efic2023/

Author:

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more